Recently TauRx Pharma presented data from their phase 3 clinical studies on a new TAU Aggregation inhibitor.
Co-founder of TAURx Pharma and Professor at Institute of Pharmacology at Charite, Franz Theuring, will share data from this study and give an insight to the some of the latest advancements in the field of Alzheimer’s disease treatment.
Sign up to attend at 澳门葡京手机版app下载sparken
Programme
13:00 –13:05: Welcome by Morten Egeberg (Leader Spark Norway) and Bjarte Reve (CEO Nansen Neuroscience Network)
13:05 –14:00: Lecture by Professor Franz Theuring
14:00 –14:30: Refreshment and networking
Abstract
Alzheimer’s disease (AD) is a complex and heterogenous neurodegenerative disease of the CNS, first presented 1907 by Alois Alzheimer, a German psychiatrist. It represents the most prevalent of the group of tauopathies, a diverse group of neurodegenerative disorders associated with cognitive and behavioural impairment in the ageing population. AD is characterised by the deposition of extracellular ?-amyloid plaques and intracellular tau neurofibrillary tangles (NFTs).
There is an urgent need for a disease-modifying treatment for AD. For the last 35 years the Pharma industry has focused on the development of drugs fighting AD on the basis of the amyloid hypothesis, whereby the formation of extracellular plaques play the major role in the disease process. However, we focus on the development of an orally administered tau protein aggregation inhibitor (TAI), hydromethylthionine mesylate (HMTM) to treat AD. NFTs and their constituent paired helical filaments (PHFs) are abnormal accumulations of aberrantly folded microtubule-associated protein tau. HMTM is a stable